The App SAA mouse joins a list of knock-in models that carry a humanized Aβ sequence within the murine App gene (App knock-in (humanized Aβ), APP NL-F Knock-in, APP NL-G-F Knock-in). As in the latter ...

A community cohort boasting 16,000 participants? A memory clinic that sees more than 2,000 patients per month? A countrywide goal of screening 80 percent of its aged population for AD? These are a few ...

According to a recent study, the view that Alzheimer’s disease damages the brain irreversibly might need to change. In December 22 Cell Reports Medicine online, scientists led by Andrew Pieper of Case ...

When TDP-43 escapes from the nucleus, cells bungle mRNA processing, chopping up and splicing transcripts in the wrong places. Most studies have focused on retention of “cryptic” exons, but recent work ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Tau PET correlates closely with cognitive decline in Alzheimer’s disease, making it a potential surrogate outcome measure. Yet in amyloid immunotherapy trials to date, this signal has not always ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...

Lecanemab has been in clinical use in the U.S. for nearly two years, and in Japan for not quite a year. How is it going? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U.S. marketing approval. What ...